On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy
It’s not a stretch to say that Greta Oberhofer is alive thanks to the genetically modified cell therapy called CAR-T. But the Novartis CAR-T wasn’t what cured Greta; her parents enrolled her in a study for a different CAR-T program, at Seattle Children’s Hospital, which was accepting patients as young as a year old. Three years later with no relapse, Greta is one of the lucky ones. The dim outlook for many others, however, has spurred Drs. Mike Jensen, Rebecca Gardner, Colleen Annesley, and their colleagues to press on with more cutting-edge versions of CAR-T that they hope in a few years are not just replacements for the Novartis therapy, but alternatives to bone marrow transplants.
About Seattle Children’s
Seattle Children’s mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children’s Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.
Ranked as one of the top children’s hospitals in the country by U.S. News & World Report, Seattle Children’s serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho – the largest region of any children’s hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children’s Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children’s Hospital and Research Foundation works with the Seattle Children’s Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research.
For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.